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Volume 51, Number 11S Abstracts 31SResults: 88% of all 163 possible access sites were closed
by FS as first choice, traditional cut-down was primarily
performed in 11.4% and percutaneus closure device was
used in 0.6%. 9% of the FS closed access sites were con-
verted to open cut-down closure intraoperatively because
of bleeding (7%) or stenosis (2%). Data from the one year
follow-up show no signs of increased stenosis, thrombosis
or formation of plaque. 4 pseudoaneurysms (3%) were
detected and 2 of these warranted surgical repair.
Conclusions: FS is technically feasible, economically
sound and appears to be a safe and effective method of
closure of femoral access sites after EVAR.Most short-term
complications are easily detected and managed intraopera-
tively. Few long-term complications were detected.
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Objectives: The Endurant (Medtronic) is a new stent-
graft designed to reduce complications while widening the
applicability of EVAR. This study presents the 1-year re-
sults of the Endurant in “real-life practise.”
Methods: All clinical pre-, per- and postoperative data
of Endurant patients of our 3 centers is prospectively col-
lected. Patients undergo CTAs preoperatively, and 1
month and yearly post-EVAR. All patients with completed
1-year follow-up were included. Clinical data, AAA charac-
teristics, presence of endoleaks (EL), graft migration (5
mm), and other EVAR related complications were noted.
All values are stated as mean (range).
Results: 66 AAA patients were included {61 male,
AAA size 63 mm (45-89), AAA volume 202 mL (68-548),
neck length 32 mm (9-70), angulation 39° (0-109)}. Pri-
mary technical success was achieved in 98.5% (1 stent
placed in renal artery) with no primary type I/III ELs or
conversions. Thirty-day mortality was 0%. On the first
postoperative CTA, 10 ELs were seen (15%, all type II).
One-year follow-up showed four iliac limb occlusions (6%,
all due to poor outflow), and 1 infected stentgraft (causing
a type I EL). Five endovascular reinterventions were per-
formed (8%; 4 to treat iliac limb occlusions, 1 proximal
extension cuff). 1-year mortality was 13.7% (9 patients).
AAA-related mortality was 1.5% (the 1 with stentgraft
infection). The mean AAA size had decreased significantly
after 1 year {diameter: 53 mm (32-80), volume: 162 mL(60-400)}, 7 ELs were noted {6 II, 1 type I (neck dilata-
tion), no graft migration}.
Conclusions: This is the first report on 1-year FU data
using the Endurant for AAA treatment. The technical
success rate was very high. Stentgraft migration did not
occur and only 1 type Ia EL was seen. The AAA-related
mortality was 1.5%, but the total 1-year mortality was
relatively high. Iliac limb occlusions were seen relatively
frequently, possibly demanding more frequent prophylac-
tic PTA of outflow vessels.
Author Disclosures: J. P. de Vries: consultant for
Medtronic, Consulting fees or other remuneration (pay-
ment); H. Dekker: Nothing to disclose; F. B. Gonçalves:
Nothing to disclose; F. L. Moll: 3Mensio, Consulting fees or
other remuneration (payment)Medtronic, Consulting fees or
other remuneration (payment); J. A. van Herwaarden:
3Mensio, Consulting fees or other remuneration (payment)
Medtronic, Consulting fees or other remuneration (pay-
ment); J. W. van Keulen: Nothing to disclose; H. J. Verha-
gen: 3Mensio, Consulting fees or other remuneration (pay-
ment) Medtronic, Consulting fees or other remuneration
(payment).
PS40.
Abdominal Aortic Aneurysms: Challenging Neck and
Difficult Access (How to Solve a Real Problem With A
New Hydrophilic and Low-profile Device)
Francesco Setacci, Pasqualino Sirignano, Rosaria Massa-
roni, Alfredo Cannizzaro, Gianmarco de Donato, Emiliano
Chisci, Giuseppe Galzerano, Alessandro Cappelli, Carlo
Setacci. Vascular and Endovascular Surgery Unit, Univer-
sity of Siena, Siena, Italy
Objectives: To evaluate the results of a new aortic
endograft for the treatment of abdominal aortic aneurysms
(AAAs) with challenging neck and/or difficult access.
Methods: The definition of a challenging proximal
neck was based on diameter (28 mm), length (15 mm),
angulations (60°), shape (reverse tapered or bulging),
thrombus lining (50%) and tortuosity. The definition of
difficult access was based on the presence of two or more
90° angulations within an iliac artery and concomitant
occlusive disease with external or common iliac artery di-
ameter less than 7mm. Between September 2008 and No-
vember 2009, 46 patients (39 male, mean age 75.82 years)
were treated with the Endurant stent-graft (Medtronic,
Santa Rosa, CA, USA) in our unit. Nine of the 46 patients
(19.56%) had a challenging neck, 13 (28.26%) had hostile
iliac artery anatomy, and 24 (52.18%) had both. The results
were analyzed in terms of technical success, 1-month mor-
tality and morbidity and aorto-iliac complications (en-
doleaks and iliac injuries).
Results: Technical success was achieved in all cases.
Two (4.34%) type-1 endoleaks were detected on comple-
tion angiography (CA) and solved by means of proximal
ballooning. Three (6.52%) type-2 endoleaks detected on
CA were seen to have resolved spontaneously on 1-month
